30 Days Countdown: Record Global Participation Highlights CISCE's Commitment to Connectivity, Cooperation and Innovation
To date, 650+ companies and institutions from 75 countries and regions have confirmed their cooperation, with 35% of exhibitors coming from overseas—half of those from Europe and the U.S. Over 65% of participants are from Fortune 500 companies or industry leaders, while total exhibitor engagement—including supply chain affiliates—is projected to reach 1,200. The expo is expected to welcome 200,000+ professional and general visitors through both in-person and digital platforms.
Thailand has been named as this year's Guest Country of Honor, with China's Shandong and Guangdong provinces as Guest Provinces of Honor.
The landmark CISCE 2025 Beijing Initiative s will be unveiled during the event, while the third annual Global Supply Chain Promotion Report will also be released at the Expo, providing actionable insights for international cooperation.
Exhibitions will showcase breakthrough innovations and collaborative achievements across seven core sectors: Advanced Manufacturing, Smart Vehicle s, Green Agriculture, Clean Energy, Digital Technology, Healthy Living, and Supply Chain Services. A slate of forums and side events will bring together industry pioneers, thought leaders, and specialists to chart new frontiers for global industrial and supply chain cooperation.
Innovation will be front and center at CISCE 2025 with the debut of the Innovation Chain Zone, highlighting trailblazing work from 14 top-tier institutions, including WIPO and the China National Intellectual Property Administration, and demonstrating their end-to-end innovation ecosystems. The event will host 100+ global product launches and unveilings —a 10% increase from 2024—alongside the rollout of the CISCE New Product Hub, the Global Supply Chain Index Matrix, and a Visualized Industrial Map.
Upholding its commitment to eco-friendly, low-carbon, and sustainable operations, the Expo will offer exhibitors personalized concierge services, while providing visiting delegations with customized solutions. Registration is now open for trade visitors, buyers, media, and the general public, with free admission for all guests.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
6 hours ago
- Korea Herald
Sirtex Medical's SIR-Spheres® Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable Hepatocellular Carcinoma
Expanded indication makes SIR-Spheres ® the first and only radioembolization therapy in the U.S. approved to treat both unresectable hepatocellular carcinoma and metastatic colorectal cancer WOBURN, Mass., July 7, 2025 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of interventional oncology solutions, today announced that the U.S. Food and Drug Administration (FDA) approved SIR-Spheres ® Y-90 resin microspheres for the treatment of unresectable hepatocellular carcinoma (HCC) in the United States. With this approval, SIR-Spheres ® is the only radioembolization therapy approved for the treatment of both metastatic colorectal cancer (mCRC) of the liver and HCC in the U.S. HCC is the most common form of liver cancer in adults in the U.S., according to the American Cancer Society. Radioembolization–commonly referred to as selective internal radiation therapy (SIRT)–with SIR-Spheres ® uses personalized dosimetry to deliver the optimal dose of radiation directly to tumors in patients with HCC. This approval gives clinicians expanded flexibility in selecting a liver-directed therapy that aligns with patient-specific needs and treatment goals. "The expanded indication makes SIR-Spheres ® the only Y-90 treatment approved in the U.S. for both HCC and mCRC," said Matt Schmidt, CEO of Sirtex. "This milestone reflects our ongoing commitment to delivering flexible, personalized therapies—with multiple dose options available daily—that empowers physicians to treat patients when and where it works best." This regulatory milestone is supported by results from the DOORwaY 90 study, a prospective, multicenter, open-label clinical trial evaluating the safety and efficacy of SIR-Spheres ® in treating HCC. The study enrolled 100 patients across 18 U.S. centers, with 65 patients included in the interim primary efficacy cohort. DOORwaY 90 met its prespecified co-primary endpoints, demonstrating a best overall response rate (ORR) of 98.5% as assessed by independent central review. All evaluable patients demonstrated a response, indicating a 100% local tumor control rate. Additionally, the median duration of response (DoR) exceeded 300 days. These findings highlight SIR-Spheres ® as a highly effective liver-directed therapy with a favorable safety profile. "This study moves the field of radioembolization forward with reproducible dosimetry outcomes and a strong safety profile linked to very positive clinical results," said Dr. Armeen Mahvash, Interventional Radiologist at MD Anderson Cancer Center and Co-Principal Investigator of the DOORwaY 90 Study. "This will give multidisciplinary care teams the confidence to recommend SIR-Spheres ® for HCC treatment." For more information and details on how to incorporate SIR-Spheres ® into your practice, please contact Sirtex at info-use@ About SIR-Spheres ® SIR-Spheres ® Y-90 resin microspheres are indicated for the local tumor control of unresectable hepatocellular carcinoma (HCC) in patients with no macrovascular invasion, Child-Pugh A cirrhosis, well-compensated liver function, and good performance status. They are also indicated for the treatment of unresectable metastatic liver tumors from primary colorectal cancer with adjuvant intra-hepatic artery chemotherapy (IHAC) of FUDR (Floxuridine). Caution: Federal (USA) law restricts this device for sale by or on the order of a physician. Consult the Instructions for Use ( for a complete listing of indications, contraindications, side effects, warnings and precautions. About Sirtex Sirtex Medical is a global healthcare company focused on advancing minimally invasive, liver-directed cancer and embolization therapies. With offices in the U.S., Australia, Europe, and Asia, Sirtex delivers innovative interventional oncology and embolization solutions to physicians and patients worldwide. The company's lead product, SIR-Spheres ® Y-90 resin microspheres, is now the only FDA approved product in the United States indicated for both the treatment of hepatocellular carcinoma (HCC) and metastatic colorectal cancer (mCRC). For more information, visit
Korea Herald
8 hours ago
- Korea Herald
CJ AI R&D Division to Launch Millstone CUE in August, a Game Changer in Content Creation
SEOUL, South Korea, July 7, 2025 /PRNewswire/ -- CJ Group will launch its AI-powered video solution, Millstone CUE, this August, offering comprehensive services from video search and editing to content generation. The initial release will focus on automatically detecting and blurring people and objects within videos, with additional features to follow. Millstone CUE integrates proprietary AI Blur and AI Remover technologies that automatically detect and either blur or seamlessly remove individuals, brand logos and filming equipment appearing in video footage. Moving beyond traditional manual editing, the system understands the full context of a video and processes it automatically. Extensive testing has confirmed it can reduce editing time by up to 91 percent. CJ ENM first deployed AI Blur in internal video production workflows, validating its accuracy and performance. It was used in YouTube content featuring K-pop group ZEROBASEONE and Mnet's WORLD OF STREET WOMAN FIGHTER, accelerating the delivery of polished, professional videos. Following the official launch, Millstone CUE will be available to creators, broadcasters and businesses, making advanced video editing tools more accessible across the content industry. Unlike existing services, Millstone CUE uses proprietary AI to identify and track people and objects without the need for reference images. It performs reliably across a variety of angles, lighting conditions and distances. Patent applications have been filed in both Korea and international markets. Creators often struggle to properly remove sensitive or unwanted content due to time and budget constraints, while videos featuring numerous individuals are widely and indiscriminately shared. The exposure of individuals' faces without consent poses serious risks of privacy violations, unauthorized use and even potential criminal misuse. Unwanted elements such as filming equipment can also detract from a video's overall quality and viewer experience. Millstone CUE offers a solution. It safeguards individual rights and automates repetitive, labor-intensive editing tasks through AI, allowing creators to focus on creative expression. The tool enables content production that is efficient, ethically responsible and delivers both speed and integrity in the creative process, including CG/VFX workflows. CJ Group sees Millstone CUE as a pivotal step toward a paradigm shift in how content is created. The company plans to enhance the platform with AI innovations across video search, editing and generation to elevate content quality and viewer engagement. "Millstone CUE marks the beginning of our journey to transform culture through AI," said CHihoon Lee, head of CJ's AI R&D Division. "Our AI technology acts as a creative collaborator and enabler, helping produce immersive, high-quality content. We are shaping the future of Korea-focused AI, building on our global technological strengths to lead the next wave of cultural innovation."
Korea Herald
15 hours ago
- Korea Herald
Topview AI Unveils the World's First AI Avatar That Can Wear, Sit On, and Showcase Any Product -- Not Just Hold It.
No studio. No model. Just AI-powered, product-perfect video in minutes. SINGAPORE, July 7, 2025 /PRNewswire/ -- In a major leap forward for AI-generated content and e-commerce marketing, Topview AI today unveiled Topview Avatar 2, the world's first AI avatar technology that can wear, sit on, and showcase nearly any type of product — not just hold it. While traditional AI avatars are limited to basic hand-held gestures with phones or mugs, Topview Avatar 2 introduces full-body interaction. Now, brands can create AI-generated videos where avatars walk in outfits, try on sunglasses, sit on sofas, and even demonstrate large products — all with studio-level realism. " This changes everything about how product videos are made," said Jensen Wu, Co-Founder & CEO of Topview AI. " For the first time, marketers can bring any product to life — worn, showcased, or demonstrated — without shoots, studios, or talent. It's AI-powered storytelling that looks and feels real, but scales like software." From Product Image to Full UGC-Style Video — in Minutes Topview AI's workflow is stunningly simple: users upload a product image, select from 1,000+ ready-to-use avatars, and get a full UGC-style video where the avatar talks, moves, and interacts with the product in a natural way. Powered by proprietary generative AI, Topview Avatar 2 delivers: A Game-Changer for DTC, Ecommerce, and Global Brands As marketing teams battle rising costs, influencer fatigue, and content localization challenges, Topview AI offers a radical solution: Already adopted by hundreds of Shopify sellers, Amazon merchants, and global DTC brands, Topview Avatar 2 is now live with a free trial at Headquartered in Singapore, Topview AI is a global leader in generative AI for marketing video production. Its platform empowers e-commerce brands to create scalable, studio-quality videos — instantly and without filming. Topview AI's tools, including Product Avatar and Anyshoot, are used by marketers across 120+ countries.
